patients with back acne were pooled and analyzed from both phase 3 studies. In the chest acne group, 421 patients received placebo and 418 patients received sarecycline. In the back-acne group, 561 patients received placebo and 573 patients received sarecycline. Demographic variables and baseline disease characteristics were similar across treatment groups for both chest and back populations (Table 1). Most patients in both chest and back populations had an IGA score of 2 (53–67%).
Pooled IGA Success in Chest Acne
In the individual studies, IGA success rate was significantly greater in the sarecycline group compared to the placebo group at weeks 6 (21.5% vs 14.6%, respectively; P=0.020) and 12 (29.6% vs 19.6%, respectively; P=0.006) for study SC1401 and at week 12 (21.6% vs 36.6%, respectively; P<0.001) for study SC1402 (Figure 2A-B). Pooled IGA success rate was significantly greater in the sarecycline group than in the placebo group at week 3 (11.84%
